New naloxone nasal spray at least doubles the dose
The Food and Drug Administration today approved a naloxone hydrochloride nasal spray to treat opioid overdoses that delivers 8 milligrams of naloxone, up from 2 mg or 4 mg in previously approved products.
“Addressing the opioid crisis is a top priority for the FDA, and we will continue our efforts to increase access to naloxone and place this important medicine in the hands of those who need it most,” said Patrizia Cavazzoni, M.D., director of FDA’s Center for Drug Evaluation and Research.
Related News Articles
Headline
The Department of Health and Human Services and the Department of Justice Oct. 22 announced a six-month anti-fraud healthcare self-disclosure pilot program for…
Headline
The Department of Health and Human Services has delegated the Centers for Medicare & Medicaid Services certain statutory authorities to exclude individuals…
Headline
Multiple changes to transparency in coverage requirements for insurers were finalized Oct. 5 by the Departments of the Treasury, Labor, and Health and Human…
Headline
The AHA Aug. 31 joined a coalition led by LeadingAge and other national healthcare organizations in submitting comments to the Centers for Medicare &…
Headline
In this conversation, Caroline DeLongchamps, director of the patient- and family-centered care program at MUSC Health, shares a powerful personal story and…
Headline
The AHA Aug. 11 published a new issue brief on how hospitals and health systems can incorporate care navigation and coordination into their patient care…